The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
Xiaoyuan Chen - One of the best experts on this subject based on the ideXlab platform.
-
glucagon like peptide 1 receptor pet ct with 68ga nota exendin 4 for detecting localized Insulinoma a prospective cohort study
The Journal of Nuclear Medicine, 2016Co-Authors: Yaping Luo, Yupei Zhao, Qingqing Pan, Shaobo Yao, Huadan Xue, Dale O Kiesewetter, Zhaohui Zhu, Xiaoyuan ChenAbstract:Preoperative localization of Insulinoma is a clinical dilemma. We aimed to investigate whether glucagon-like peptide-1 receptor (GLP-1R) PET/CT with 68Ga-NOTA-MAL-cys40-exendin-4 (68Ga-NOTA-exendin-4) is efficient in detecting Insulinoma. Methods: In our prospective cohort study, patients with endogenous hyperinsulinemic hypoglycemia were enrolled. CT, MRI, endoscopic ultrasound, and 99mTc-hydrazinonicotinamide-TOC SPECT/CT were done according to standard protocols. GLP-1R PET/CT was performed 30–60 min after the injection of 68Ga-NOTA-exendin-4. The gold standard for diagnosis was the histopathologic results after surgery. Results: Of 52 recruited patients, 43 patients with histopathologically proven Insulinomas were included for the imaging studies. Nine patients did not undergo surgical intervention. 68Ga-NOTA-exendin-4 PET/CT correctly detected Insulinomas in 42 of 43 patients with high tumor uptake (mean SUVavg ± SD, 10.2 ± 4.9; mean SUVmax ± SD, 23.6 ± 11.7), resulting in sensitivity of 97.7%. In contrast, 99mTc-hydrazinonicotinamide-TOC SPECT/CT showed a low sensitivity of 19.5% (8/41) in this group of patients; however, it successfully localized the tumor that was false-negative with GLP-1R PET/CT. The sensitivities of CT, MR, and endoscopic ultrasonography were 74.4% (32/43), 56.0% (14/25), and 84.0% (21/25), respectively. Conclusion:68Ga-NOTA-exendin-4 PET/CT is a highly sensitive imaging technique for the localization of Insulinoma.
-
pet of Insulinoma using 18f fbem em3106b a new glp 1 analogue
Molecular Pharmaceutics, 2011Co-Authors: Dale O Kiesewetter, Haokao Gao, Gang Niu, Min Yang, Qimeng Quan, Eunice N Murage, Jungmo Ahn, Xiaoyuan ChenAbstract:Derived from endocrine pancreatic beta cells, Insulinomas express glucagon-like peptide-1 (GLP-1) receptor with high density and incidence. In this study, we labeled a novel GLP-1 analogue, EM3106B, with 18F and performed PET imaging to visualize Insulinoma tumors in an animal model. A GLP-1 analogue that contains multiple lactam bridges, EM3106B, was labeled with 18F through a maleimide-based prosthetic group, N-2-(4-18F-fluorobenzamido)ethylmaleimide (18F-FBEM). The newly developed radiotracer was characterized by cell based receptor-binding assay, cell uptake and efflux assay. The stability in serum was evaluated by radio-HPLC analysis. In vivo PET imaging was performed in nude mice bearing subcutaneous INS-1 Insulinoma tumors and MDA-MB-435 tumors of melanoma origin. Ex vivo biodistribution study was performed to confirm the PET imaging data. EM3106B showed high binding affinity (IC50 = 1.38 nM) and high cell uptake (5.25 ± 0.61% after 120 min incubation). 18F-FBEM conjugation of EM3106B resulted in h...
Alessio Imperiale - One of the best experts on this subject based on the ideXlab platform.
-
Effect of Carbidopa on 18 F-FDOPA Uptake in Insulinoma: From Cell Culture to Small-Animal PET Imaging
Journal of Nuclear Medicine, 2017Co-Authors: Julien Detour, Alice Pierre, Fréderic Boisson, Guillaume Kreutter, Thomas Lavaux, Izzie Jacques Namer, Laurence Kessler, David Brasse, Patrice Marchand, Alessio ImperialeAbstract:Patient premedication with carbidopa seems to improve the accuracy of 6-F-18-fluoro-3,4-dihydroxy-L-phenylalanine (F-18-FDOPA) PET for Insulinoma diagnosis. However, the risk of PET false-negative results in the presence of carbidopa is a concern. Consequently, we aimed to evaluate the effect of carbidopa on F-18-FDOPA uptake in Insulinoma beta-cells and an Insulinoma xenograft model in mice. Methods: F-18-FDOPA in vitro accumulation was assessed in the murine beta-cell line RIN-m5F. In vivo small-animal PET experiments were performed on tumor-bearing nude mice after subcutaneous injection of RIN-m5F cells. Experiments were conducted with and without carbidopa pretreatment. Results: Incubation of RIN-m5F cells with 80 mu M carbidopa did not significantly affect the cellular accumulation of F-18-FDOPA. Tumor xenografts were clearly detectable by small-animal PET in all cases. Insulinoma xenografts in carbidopa-treated mice showed significantly higher F-18-FDOPA uptake than those in nontreated mice. Regardless of carbidopa premedication, the xenografts were characterized by an early increase in F-18-FDOPA uptake and then a progressive reduction over time. Conclusion: Carbidopa did not influence in vitro F-18-FDOPA accumulation in RIN-m5F cells but improved Insulinoma imaging in vivo. Our findings increase current knowledge about the F-18-FDOPA uptake profile of RIN-m5F cells and a related xenograft model. To our knowledge, the present work represents the first pre clinical research specifically focused on Insulinomas, with potential translational implications.
-
Carbidopa Effect on 18F-FDOPA Uptake in Insulinoma: from Cell Culture to microPET Imaging
Journal of nuclear medicine : official publication Society of Nuclear Medicine, 2016Co-Authors: Julien Detour, Alice Pierre, Fréderic Boisson, Guillaume Kreutter, Thomas Lavaux, Izzie Jacques Namer, Laurence Kessler, David Brasse, Patrice Marchand, Alessio ImperialeAbstract:Patient premedication with carbidopa seems to improve the accuracy of 6-F-18-fluoro-3,4-dihydroxy-L-phenylalanine (F-18-FDOPA) PET for Insulinoma diagnosis. However, the risk of PET false-negative results in the presence of carbidopa is a concern. Consequently, we aimed to evaluate the effect of carbidopa on F-18-FDOPA uptake in Insulinoma beta-cells and an Insulinoma xenograft model in mice. Methods: F-18-FDOPA in vitro accumulation was assessed in the murine beta-cell line RIN-m5F. In vivo small-animal PET experiments were performed on tumor-bearing nude mice after subcutaneous injection of RIN-m5F cells. Experiments were conducted with and without carbidopa pretreatment. Results: Incubation of RIN-m5F cells with 80 mu M carbidopa did not significantly affect the cellular accumulation of F-18-FDOPA. Tumor xenografts were clearly detectable by small-animal PET in all cases. Insulinoma xenografts in carbidopa-treated mice showed significantly higher F-18-FDOPA uptake than those in nontreated mice. Regardless of carbidopa premedication, the xenografts were characterized by an early increase in F-18-FDOPA uptake and then a progressive reduction over time. Conclusion: Carbidopa did not influence in vitro F-18-FDOPA accumulation in RIN-m5F cells but improved Insulinoma imaging in vivo. Our findings increase current knowledge about the F-18-FDOPA uptake profile of RIN-m5F cells and a related xenograft model. To our knowledge, the present work represents the first pre clinical research specifically focused on Insulinomas, with potential translational implications.
-
Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia.
Clinical nuclear medicine, 2015Co-Authors: Alessio Imperiale, Thibault Bahougne, Bernard Goichot, Philippe Bachellier, David Taïeb, Izzie Jacques NamerAbstract:(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia. Carbidopa is an efficient inhibitor of the peripheral aromatic amino acid decarboxylase, significantly reducing the physiological pancreatic FDOPA uptake. Nevertheless, carbidopa effect on FDOPA uptake in Insulinomas is not fully elucidated. No final consensus has been reached about the usefulness of carbidopa in patients with Insulinoma-related hyperinsulinemic hypoglycemia. Moreover, the ideal timing for PET/CT acquisitions is a matter of discussion. We report the results of dynamic FDOPA PET performed after carbidopa premedication in 2 adult patients with Insulinoma.
Izzie Jacques Namer - One of the best experts on this subject based on the ideXlab platform.
-
Effect of Carbidopa on 18 F-FDOPA Uptake in Insulinoma: From Cell Culture to Small-Animal PET Imaging
Journal of Nuclear Medicine, 2017Co-Authors: Julien Detour, Alice Pierre, Fréderic Boisson, Guillaume Kreutter, Thomas Lavaux, Izzie Jacques Namer, Laurence Kessler, David Brasse, Patrice Marchand, Alessio ImperialeAbstract:Patient premedication with carbidopa seems to improve the accuracy of 6-F-18-fluoro-3,4-dihydroxy-L-phenylalanine (F-18-FDOPA) PET for Insulinoma diagnosis. However, the risk of PET false-negative results in the presence of carbidopa is a concern. Consequently, we aimed to evaluate the effect of carbidopa on F-18-FDOPA uptake in Insulinoma beta-cells and an Insulinoma xenograft model in mice. Methods: F-18-FDOPA in vitro accumulation was assessed in the murine beta-cell line RIN-m5F. In vivo small-animal PET experiments were performed on tumor-bearing nude mice after subcutaneous injection of RIN-m5F cells. Experiments were conducted with and without carbidopa pretreatment. Results: Incubation of RIN-m5F cells with 80 mu M carbidopa did not significantly affect the cellular accumulation of F-18-FDOPA. Tumor xenografts were clearly detectable by small-animal PET in all cases. Insulinoma xenografts in carbidopa-treated mice showed significantly higher F-18-FDOPA uptake than those in nontreated mice. Regardless of carbidopa premedication, the xenografts were characterized by an early increase in F-18-FDOPA uptake and then a progressive reduction over time. Conclusion: Carbidopa did not influence in vitro F-18-FDOPA accumulation in RIN-m5F cells but improved Insulinoma imaging in vivo. Our findings increase current knowledge about the F-18-FDOPA uptake profile of RIN-m5F cells and a related xenograft model. To our knowledge, the present work represents the first pre clinical research specifically focused on Insulinomas, with potential translational implications.
-
Carbidopa Effect on 18F-FDOPA Uptake in Insulinoma: from Cell Culture to microPET Imaging
Journal of nuclear medicine : official publication Society of Nuclear Medicine, 2016Co-Authors: Julien Detour, Alice Pierre, Fréderic Boisson, Guillaume Kreutter, Thomas Lavaux, Izzie Jacques Namer, Laurence Kessler, David Brasse, Patrice Marchand, Alessio ImperialeAbstract:Patient premedication with carbidopa seems to improve the accuracy of 6-F-18-fluoro-3,4-dihydroxy-L-phenylalanine (F-18-FDOPA) PET for Insulinoma diagnosis. However, the risk of PET false-negative results in the presence of carbidopa is a concern. Consequently, we aimed to evaluate the effect of carbidopa on F-18-FDOPA uptake in Insulinoma beta-cells and an Insulinoma xenograft model in mice. Methods: F-18-FDOPA in vitro accumulation was assessed in the murine beta-cell line RIN-m5F. In vivo small-animal PET experiments were performed on tumor-bearing nude mice after subcutaneous injection of RIN-m5F cells. Experiments were conducted with and without carbidopa pretreatment. Results: Incubation of RIN-m5F cells with 80 mu M carbidopa did not significantly affect the cellular accumulation of F-18-FDOPA. Tumor xenografts were clearly detectable by small-animal PET in all cases. Insulinoma xenografts in carbidopa-treated mice showed significantly higher F-18-FDOPA uptake than those in nontreated mice. Regardless of carbidopa premedication, the xenografts were characterized by an early increase in F-18-FDOPA uptake and then a progressive reduction over time. Conclusion: Carbidopa did not influence in vitro F-18-FDOPA accumulation in RIN-m5F cells but improved Insulinoma imaging in vivo. Our findings increase current knowledge about the F-18-FDOPA uptake profile of RIN-m5F cells and a related xenograft model. To our knowledge, the present work represents the first pre clinical research specifically focused on Insulinomas, with potential translational implications.
-
Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia.
Clinical nuclear medicine, 2015Co-Authors: Alessio Imperiale, Thibault Bahougne, Bernard Goichot, Philippe Bachellier, David Taïeb, Izzie Jacques NamerAbstract:(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia. Carbidopa is an efficient inhibitor of the peripheral aromatic amino acid decarboxylase, significantly reducing the physiological pancreatic FDOPA uptake. Nevertheless, carbidopa effect on FDOPA uptake in Insulinomas is not fully elucidated. No final consensus has been reached about the usefulness of carbidopa in patients with Insulinoma-related hyperinsulinemic hypoglycemia. Moreover, the ideal timing for PET/CT acquisitions is a matter of discussion. We report the results of dynamic FDOPA PET performed after carbidopa premedication in 2 adult patients with Insulinoma.
David Taïeb - One of the best experts on this subject based on the ideXlab platform.
-
Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia.
Clinical nuclear medicine, 2015Co-Authors: Alessio Imperiale, Thibault Bahougne, Bernard Goichot, Philippe Bachellier, David Taïeb, Izzie Jacques NamerAbstract:(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia. Carbidopa is an efficient inhibitor of the peripheral aromatic amino acid decarboxylase, significantly reducing the physiological pancreatic FDOPA uptake. Nevertheless, carbidopa effect on FDOPA uptake in Insulinomas is not fully elucidated. No final consensus has been reached about the usefulness of carbidopa in patients with Insulinoma-related hyperinsulinemic hypoglycemia. Moreover, the ideal timing for PET/CT acquisitions is a matter of discussion. We report the results of dynamic FDOPA PET performed after carbidopa premedication in 2 adult patients with Insulinoma.
-
limited value of 18f f dopa pet to localize pancreatic insulin secreting tumors in adults with hyperinsulinemic hypoglycemia
The Journal of Clinical Endocrinology and Metabolism, 2010Co-Authors: Laurent Tessonnier, F Sebag, C Ghander, C De Micco, R Reynaud, F F Palazzo, B Contedevolx, J F Henry, Olivier Mundler, David TaïebAbstract:Context: Fluorine-18-l-dihydroxyphenylalanine positron emission tomography (18F-FDOPA PET) imaging is increasingly used in the workup of neuroendocrine tumors. It has been shown to be an accurate tool in the diagnosis of congenital hyperinsulinism, but limited information is available on its value in adult disease. Objective, Patients, and Design: The objective of this study was to review our experience with 18F-FDOPA PET imaging in six consecutive patients with hyperinsulinemic hypoglycemia (HH) (four solitary Insulinomas, one diffuse β-cell hyperplasia, one malignant Insulinoma). 18F-FDOPA uptake was also evaluated in 37 patients (43 procedures) without HH or other pancreatic neuroendocrine tumors, which acted as a control group. Results: Using visual analysis, 18F-FDOPA-PET proved positive in only one case (a multiple endocrine neoplasia type 1 related Insulinoma). In diffuse β-cell hyperplasia, the pancreatic uptake was similar to controls. In the patient with liver metastases, the extent of disease w...
Haokao Gao - One of the best experts on this subject based on the ideXlab platform.
-
pet of Insulinoma using 18f fbem em3106b a new glp 1 analogue
Molecular Pharmaceutics, 2011Co-Authors: Dale O Kiesewetter, Haokao Gao, Gang Niu, Min Yang, Qimeng Quan, Eunice N Murage, Jungmo Ahn, Xiaoyuan ChenAbstract:Derived from endocrine pancreatic beta cells, Insulinomas express glucagon-like peptide-1 (GLP-1) receptor with high density and incidence. In this study, we labeled a novel GLP-1 analogue, EM3106B, with 18F and performed PET imaging to visualize Insulinoma tumors in an animal model. A GLP-1 analogue that contains multiple lactam bridges, EM3106B, was labeled with 18F through a maleimide-based prosthetic group, N-2-(4-18F-fluorobenzamido)ethylmaleimide (18F-FBEM). The newly developed radiotracer was characterized by cell based receptor-binding assay, cell uptake and efflux assay. The stability in serum was evaluated by radio-HPLC analysis. In vivo PET imaging was performed in nude mice bearing subcutaneous INS-1 Insulinoma tumors and MDA-MB-435 tumors of melanoma origin. Ex vivo biodistribution study was performed to confirm the PET imaging data. EM3106B showed high binding affinity (IC50 = 1.38 nM) and high cell uptake (5.25 ± 0.61% after 120 min incubation). 18F-FBEM conjugation of EM3106B resulted in h...
